RB1 Knockout Cell Line (HEK293)

The choice depends on whether you are studying RB1's role as the founding tumor suppressor and master regulator of the G1/S checkpoint or its specific contributions to E2F repression and chromatin modification. The Knockout line is the standard tool for asking whether RB1 is required for restraining E2F-mediated S-phase entry — RB1 is the prototypical tumor suppressor, loss of which leads to uncontrolled E2F target gene expression and cell cycle deregulation. Overexpression is useful for studying RB1 in cancer contexts where it has been reported as a tumor suppressor or for testing constitutively active (phospho-mimetic resistant) RB1 mutants. For tumor suppressor research, the EDITGENE RB1 Knockout in HEK293 is a workhorse mechanistic platform — RB1 loss has been extensively studied in cell cycle biology and cancer. Rescue with wild-type, phosphorylation-resistant (PSM7, 7 CDK site mutations), or hotspot mutant RB1 enables comprehensive structure-function studies. The knockout is valuable for testing CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) — RB1 status is a clinical biomarker for CDK4/6 inhibitor response.

Primary applications: • Cell cycle progression: flow cytometry-based cell cycle analysis and S-phase entry kinetics in the RB1-null background. • E2F target gene expression: RNA-seq analysis of E2F target genes (cyclin E, CDK1, MCM proteins) to characterize RB1's transcriptional repression role. • CDK4/6 inhibitor response: palbociclib, ribociclib, and abemaciclib sensitivity studies in RB1-null versus rescued cells — RB1 status is a clinical biomarker for CDK4/6 inhibitor response. • Tumor suppressor functions: assessment of proliferation, senescence, and DNA damage responses in the RB1-null context. EDITGENE recommends this model for researchers investigating cell cycle regulation, tumor suppressor biology, and CDK4/6 inhibitor pharmacology.

Yes. RB1 rescue experiments are well-established for tumor suppressor research: • Construct design: use a codon-modified RB1 sequence with a small C-terminal tag (FLAG, HA). RB1 has N-terminal RbN region, central A and B pocket domains, and C-terminal region — preserve all elements. • Phosphorylation-resistant rescue: PSM7 RB1 (7 CDK phosphorylation site mutations to alanine) is constitutively active (always-bound to E2F) and is invaluable for distinguishing CDK-regulated from constitutive RB1 functions. • Hotspot mutation rescue: cancer-associated RB1 mutations enable disease genotype-function studies. • Functional readout: rescue should restore E2F target gene repression and G1/S checkpoint control. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.